Page 113 - CIBEREHD2016-ENG

term safety of anti-TNF treatment in children” (coordinating 30 European centers). / Epidemiologic study
about IBD incidence in Spain (coordinating over 200 centers).
• Investigación traslacional. Desde el laboratorio de este grupo actualmente se dirigen proyectos
relacionados con:
Immune response / Mechanisms of production of antibodies against anti-TNF treatments, and their relation with treatment response. / Characterization of circulating and intestinal dendritic cells and monocytes in IBD patients. / Identification of the mechanisms mediating the mucosa recruitment of circulating dendritic cell and monocyte subsets. / Identification and characterization of novel bioactive peptides secreted by the commensal microbiota with immunomodulatory properties over the intestinal mucosa. / Novel Biomarkers based on: - Homing profile of circulating dendritic cell and monocyte subsets. - Circulating antibodies against microbiota peptides. / Therapeutic targets / Identification of the mechanisms driving the altered phenotype and functional and intestinal dendritic cells and macrophages.
Most relevant scientific articles
• Fallone C.A., Chiba N., van Zanten S.V., Fischbach L., Gisbert J.P., Hunt R.H. et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016;151(1):51-69.e14.
• Nyssen O.P., McNicholl A.G., Megraud F., Savarino V., Oderda G., Fallone C.A. et al. Sequential versus standard triple first-line therapy for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews. 2016;2016(6).
• Gisbert J.P., Marin A.C., Chaparro M.. The risk of relapse after Anti-TNF discontinuation in inflammatory bowel disease: Systematic review and meta-analysis. American Journal of Gastroenterology. 2016;111(5):632-647.
• Fernandez-Banares F., Casanova M.J., Arguedas Y., Beltran B., Busquets D., Fernandez J.M. et al. Current concepts on microscopic colitis: Evidence-based statements and recommendations of the Spanish Microscopic Colitis Group. Alimentary Pharmacology and Therapeutics. 2016;43(3):400-426.
• Feagan B.G., Sandborn W.J., Gasink C., Jacobstein D., Lang Y., Friedman J.R. et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. New England Journal of Medicine. 2016;375(20):1946-1960.
Hightlights
In 2016, at the initiative of this group, an agreement was signed with the Platform for Collaborative Research AEG-REDCap (directed from this group) to establish a Strategic Line at CIBEREHD. This platform includes over 50 research projects and 1,000 researchers.
The group has consolidated its leadership in clinical research in Inflammatory Bowel Disease (IBD) and H. pylori infection, coordinating several national and international multicenter studies, with the participation of several CIBEREHD centers.
In the area of H. pylori, we have coordinated and participated in several consensus conferences (Canadian/ European/Spanish). The European Registry on Helicobacter has reached the 20.000 registered patients, and this data has been monitored and analyzed.
In IBD, the group has coordinated and participated in several clinical trials at different stages as well as on observational studies. We have obtained public funds in several competitive calls. At present, the group is coordinating studies aiming to know the epidemiology of IBD, as well as generating a wide collection of biological samples. In addition, it is currently coordinating several studies aiming to optimize the therapy
with biologics, as well as to identify when the treatment can be discontinued. All this research is being carried out within the framework of the CIBEREHD-Strategic-Line of research in IBD. Finally, the group participated in various clinical guidelines on IBD.
In the laboratory, the group has established several collaborations with National and International centres, and obtained funding from some scientific associations. It has incorporated a post-doctoral researcher and 2 research technicians, allowing a deeper insight on the study of the phenotype and function of human intestinal dendritic cell and macrophage subsets, as well as on the mechanisms mediating their recruitment towards the mucosa from their circulating precursors and the identification of novel microbiota-secreted immunomodulatory peptides.
EHD
research Groups 113